Best Practice Series: Type 2 Diabetes

Compounds that effect GLP-1, GIP and DPP-4.

The Incretin Pathway: A new area of treatment for Type 2 diabetes.

Aug 26, 2010 | Best Practice Series: Type 2 Diabetes

Zachary Bloomgarden, MD, Editor of The Journal of Diabetes and Clinical Professor in the Dept. of Medicine at the Mount Sinai School of Medicine, discusses the use of drugs that affect the incretin pathway in treating diabetes. Disclosures:Speaker’s Bureau: Merck, NovoNordisk, GSKAdvisory Panel:...

More...

4:25

Best Practice Series in Diabetes - Type 2

Screening for Microvascular Complications in Type 2 Diabetes: Is it cost effective?

Aug 2, 2010 | Best Practice Series: Type 2 Diabetes

Zachary Bloomgarden, MD, Editor of The Journal of Diabetes and Clinical Professor in the Dept. of Medicine at the Mount Sinai School of Medicine, discusses screening of various microvascular complications of type 2 diabetes and evaluates their cost-effectiveness. Disclosures:Speaker’s Bureau: Merck,...

More...

2:38

Best Practice Series in Diabetes - Type 2

Continuous Subcutaneous Insulin: Is there a role in type 2 dabetes?

Aug 2, 2010 | Best Practice Series: Type 2 Diabetes

Zachary Bloomgarden, MD, Editor of The Journal of Diabetes and Clinical Professor in the Dept. of Medicine at the Mount Sinai School of Medicine, discusses the optimal use of insulin in treatment for diabetes. Disclosures:Speaker’s Bureau: Merck, NovoNordisk, GSKAdvisory Panel: Merck, BMS, Astra...

More...